NCT00000772View on ClinicalTrials.gov

A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1995

Conditions
HIV Infections
Interventions
DRUG

Ribavirin

DRUG

Didanosine

Trial Locations (2)

55455

University of Minnesota, ACTU, Minneapolis

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

ICN Pharmaceuticals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH